FIGURE: 1 / 2
Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.
Atezolizumab is a fully humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of metastatic non-small cell lung cancer (NSCLC). It binds to the protein programmed cell death-ligand 1 (PD-L1) on several tumors. Atezolizumab has ability to block the binding of PD-L1 with PD-1 and CD80 receptors (B7-1Rs), which has a positive effect on improving an anti-tumor response.GenScript MonoRab™ Anti-Atezolizumab Antibody (43H11), mAb, Rabbit is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a rabbit immunized with Atezolizumab.
Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). Atezolizumab blocks the interaction of PD-L1 with programmed cell death protein 1 (PD-1) and CD80 receptors (B7-1Rs). PD-L1 can be highly expressed on certain tumors, which is thought to lead to reduced activation of immune cells (cytotoxic T-cells in particular) that might otherwise recognize and attack the cancer. Inhibition of PD-L1 by atezolizumab can remove this inhibitor effect and thereby engender an anti-tumor response. It is one of several ways to block inhibitory signals related to T-cell activation, a more general strategy known as "immune checkpoint inhibition."
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: MPDL3280A; RG7446; Tecentriq